Dáil Éireann Debate, Tuesday - 27 July 2021
1484. Deputy David Cullinane asked the Minister for Health further to Parliamentary Question No. 111 of 29 April 2021, if any of the four products referenced as accepted for use in the MCAP no longer meet the definition of a specified controlled drug post-Brexit; if, this will have any bearing on their supply in this State given they have already been accepted; and if he will make a statement on the matter. [33537/21]
View answerEach of the four products that have been previously accepted for use in the Medical Cannabis Access Programme (MCAP) were available in an EU member state at the time of receipt of the applications.
When applying to be accepted for use in the MCAP, two of these products, Cannepil Oral Solution and Aurora High CBD Oil Drops, cited the UK as the EU member state in which the product was available. However, it is not envisaged that Brexit will impact the supply of these two products, given that the products met the criteria of a ‘specified controlled drug’ when the applications were received.
